(NASDAQ: MDGL) Madrigal Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Madrigal Pharmaceuticals's revenue in 2024 is $0.On average, 7 Wall Street analysts forecast MDGL's revenue for 2024 to be $1,688,933,229, with the lowest MDGL revenue forecast at $1,213,742,925, and the highest MDGL revenue forecast at $2,154,891,128. On average, 7 Wall Street analysts forecast MDGL's revenue for 2025 to be $6,282,771,123, with the lowest MDGL revenue forecast at $3,045,897,819, and the highest MDGL revenue forecast at $10,127,789,325.
In 2026, MDGL is forecast to generate $15,259,971,950 in revenue, with the lowest revenue forecast at $4,344,005,826 and the highest revenue forecast at $27,020,703,150.